Ulf Hedin

Ulf Hedin

Auto-generated profile, based on publicly available information

Ulf Hedin

Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 1999 in Atherosclerosis
Verified
Journal Article
Closed access
JFJohan Frostegard
Johan Frostegard
AUAnn-Kristin Ulfgren
Ann-Kristin Ulfgren
PNPernilla Nyberg
Pernilla Nyberg
UHUlf Hedin
Ulf Hedin
JSJesper Swedenborg
Jesper Swedenborg
GHGöran K. Hansson
Göran K. Hansson

20 July 2016 in Nature
Verified
Journal Article
Open access
PDF file
YKYoko Kojima
Yoko Kojima
JVJens-Peter Volkmer
Jens-Peter Volkmer
KMKelly McKenna
Kelly McKenna
MCMete Civelek
Mete Civelek
ALAldons Jake Lusis
Aldons Jake Lusis
NLNicholas Leeper
Nicholas Leeper
Atherosclerotic lesions in mice and humans switch on a ‘don’t eat me’ signal—expression of CD47—that prevents effective removal of diseased tissue; anti-CD47 antibody therapy can normalize this defective efferocytosis, with beneficial results in several mouse models of atherosclerosis. Nicholas Leeper and colleagues demonstrate that atherosclerotic lesions in mice and humans switch on a 'don't eat me' signal — in the form of expression of the anti-phagocytic transmembrane protein CD47 — that prevents effective removal of diseased tissue. They show that administration of anti-CD47 antibodies can normalize this defective phagocytic clearance (or ‘efferocytosis’) with beneficial results in several mouse models of atherosclerosis. These results suggest that targeted pro-efferocytic therapies could have potential in cardiovascular diseases. Atherosclerosis is the disease process that underlies heart attack and stroke1. Advanced lesions at risk of rupture are characterized by the pathological accumulation of diseased vascular cells and apoptotic cellular debris2. Why these cells are not cleared remains unknown3. Here we show that atherogenesis is associated with upregulation of CD47, a key anti-phagocytic molecule that is known to render malignant cells resistant to programmed cell removal, or ‘efferocytosis’4,5,6,7. We find that administration of CD47-blocking antibodies reverses this defect in efferocytosis, normalizes the clearance of diseased vascular tissue, and ameliorates atherosclerosis in multiple mouse models. Mechanistic studies implicate the pro-atherosclerotic factor TNF-α as a fundamental driver of impaired programmed cell removal, explaining why this process is compromised in vascular disease. Similar to recent observations in cancer5, impaired efferocytosis appears to play a pathogenic role in cardiovascular disease, but is not a fixed defect and may represent a novel therapeutic target.

1 November 1990 in Arteriosclerosis: An Official Journal of the American Heart Association, Inc.
Verified
Journal Article
Closed access
PDF file
JTJ Thyberg
J Thyberg
UHU Hedin
U Hedin
MSM Sjölund
M Sjölund
LPL Palmberg
L Palmberg
BBB A Bottger
B A Bottger

1 December 2003 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
MKMonsur Kazi
Monsur Kazi
JTJohan Thyberg
Johan Thyberg
PRPiotr Religa
Piotr Religa
JRJoy Roy
Joy Roy
PEPer Eriksson
Per Eriksson
JSJesper Swedenborg
Jesper Swedenborg

1 July 1988 in Journal of Cell Biology
Verified
Journal Article
Open access
UHU Hedin
U Hedin
BBB A Bottger
B A Bottger
EFE Forsberg
E Forsberg
SJS Johansson
S Johansson
JTJ Thyberg
J Thyberg
Plasma fibronectin promotes modulation of rat arterial smooth muscle cells from a contractile to a synthetic phenotype during the first few days in primary culture. This process includes cell adhesion and spreading, loss of myofilaments, and formation of a widespread rough endoplasmic reticulum and a prominent Golgi complex. The structural reorganization is accompanied by activation of overall RNA and protein synthesis. Moreover, the cells gain the ability to replicate their DNA and divide in response to platelet-derived growth factor. Here, it is demonstrated that the power of fibronectin to bring about this change in the differentiated properties of the smooth muscle cells resides in a 105-kD cell-binding fragment, whereas a 70-kD collagen-binding fragment and a 31-kD heparin-binding fragment are inactive in this respect. Laminin, another adhesive glycoprotein and a component of the basement membrane that normally surrounds arterial smooth muscle, was contrarily found to maintain the cells in a contractile phenotype. However, with increasing time more and more cells went through the modulation into a synthetic phenotype. This "catch-up" was counteracted by a peptide that contained the cell-attachment sequence of fibronectin (Arg-Gly-Asp-Ser). Hence, it is possible that the delayed modulation on laminin was due to production of fibronectin by the cells themselves. In support of this notion, fibronectin isolated from smooth muscle cultures was found to be as effective as plasma fibronectin in stimulating the phenotypic modulation. Moreover, using a combination of chemical, immunochemical, and immunocytochemical methods, it was demonstrated that the cells secreted fibronectin as well as laminin at an increasing rate during the first 4 d in primary culture and, notably, cells cultured on laminin produced more fibronectin than cells cultured on fibronectin. Newly synthesized fibronectin was incorporated into a network of pericellular and intercellular fibrils, whereas laminin formed a more diffuse layer covering the cells in a basement membrane-like manner. Taken together, the findings suggest diverse roles for fibronectin and laminin in the control of the differentiated properties of arterial smooth muscle cells. They further indicate that the ability of arterial smooth muscle cells to produce fibronectin and laminin early in primary culture is not directly related to the phenotypic state as determined morphologically and by measurement of overall rates of RNA and protein synthesis. This may be due to the cells being able to sense the macromolecular composition of the pericellular matrix and to modify their secretory activity accordingly.(ABSTRACT TRUNCATED AT 400 WORDS)

1 January 2006 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
AHAnne-Louise Hemdahl
Anne-Louise Hemdahl
AGAnders Gabrielsen
Anders Gabrielsen
CZChaoyong Zhu
Chaoyong Zhu
PEPer Eriksson
Per Eriksson
UHUlf Hedin
Ulf Hedin
GHGöran K. Hansson
Göran K. Hansson
Objective—Neutrophil gelatinase-associated lipocalin (NGAL) modulates the activity of matrix metalloproteinase (MMP) 9, an important mediator of vascular remodeling and plaque instability in atherosclerosis. This study aimed to analyze the expression of NGAL in atherosclerotic plaques and myocardial infarction (MI).Methods and Results—Atherosclerotic apolipoprotein E (apoE)−/−× low-density lipoprotein receptor (LDLR)−/−and C57BL/6J control mice were exposed to brief hypoxic stress (10 minutes of 10% oxygen). Expression of the mouse NGAL homolog (24p3) and MMP-9 was analyzed 48 hours later by quantitative RT-PCR, immunohistochemistry, and zymography. Hypoxic stress increased NGAL/24p3 mRNA in the cardiac vasculature. NGAL/24p3 was also increased in atherosclerotic plaques of apolipoprotein E−/−× LDLR−/−mice compared with C57BL/6J mice. Mice developing MI exhibited the highest plaque mRNA expression of NGAL/24p3 and MMP-9. Zymography revealed strong proteolytic activity in areas rich in 24p3 and MMP-9 protein. Immunohistochemistry performed on human carotid endarterectomy specimens and control tissue from the internal mammary artery showed colocalization of MMP-9 and NGAL with macrophages in the atherosclerotic plaques.Conclusions—NGAL/24p3 is increased in atherosclerotic plaques and MI. Colocalization with MMP-9 in areas with high-proteolytic activity suggests a role for NGAL/24p3 in modulating the MMP-9-mediated remodeling of plaques and infarcted hearts.